Mesothelin, also known as MSLN, is a cell surface glycoprotein encoded by the MSLN gene. The mesothelin gene is located on chromosome 16 p13.3. The gene has a full length of 8 kb and a cDNA size of 213 bp. It contains an open reading frame of 1884 bp, 17 exons, and encodes 628 amino acids. The MSLN gene encodes a 71 KD precursor protein. The precursor protein is hydrolyzed by furin protease into two parts: a soluble 31 kD N-terminal protein called megakaryocyte-potentiating factor (MPF) and a 40 kD membrane-bound fragment called MSLN. Mesothelin is a differentiation antigen that exists on normal mesothelial cells. It is rarely expressed in normal tissues, but is highly expressed in tumors such as mesothelioma, lung cancer, pancreatic cancer, breast cancer, and ovarian cancer. Therefore, mesothelin may become an important target for cancer treatment. This product is a second-generation CAR lentiviral expression vector targeting Mesothelin, which can be used for in vivo and in vitro pharmacodynamic experiments.

Product name: Lenti-EF1a-Mesothelin-2nd-CAR-EGFRt

Promoter: EF1a [1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp

Tag: EGFRt [2]



1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2. EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells. At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only serve as a CAR-T screening marker, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB001A )